SecBot SecBot

TXG

10x Genomics, Inc.
Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001770787 Genomics & Gene Editing
$55.33 −2.86 (−4.91%)
Nov 16 4:00 PM ET · prev $58.19
Market cap
$7.8B
Mid cap
Consensus
Buy
48% Buy or better · 21 analysts
Median target
$65.00
+17% · range $50.00–100.00
1 year
+252.4%
from $15.70 · Nov 17
30 days
−20.8%
from $69.86
52-week range
$15.46–97.74
−43% from high · low Dec 12
Avg volume 20D
3.14M
shares / day
Short interest
12.47M
≈9.5% of shares · −2.0%
Days to cover
4.1
at average volume
Insider net
−$17.2M
0 buyers · 6 sellers · since Mar 23
New fund stakes
4
Q2 2026 13F · 2 exits
Reddit crowd
42°
Neutral · 2 mentions this week
SecBot read MIXED 16 reports · 90 days
Balance 2 bearish · 1 bullish · 2 mixed · 11 neutral oldest → newest, height = score
Avg score ·High conf. 9/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $17.2M.

  • InstitutionsMIXED

    Q2 2026: 28 added (4 new), 23 trimmed or exited. Largest new: Point72 Asset Management, $71.0M, Jane Street Group $28.9M.

  • AnalystsBULLISH

    10 of 21 rate it Buy or better. Median target $65.00 (+17%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.003 → −$0.040 over 90 days.

  • Short sellersSTEADY

    Short interest −2.0% to 12.47M shares. 4.1 days to cover, ≈9.5% of shares.

  • TrendDOWNTREND

    25% below its 50-day average.

  • SocialQUIET

    Crowd 42° (neutral) this week from 2 mentions: 0 bullish, 1 bearish. No setup is alerting.

Who's buying

13F· Q2 2026
4
new positions
2
exits
$126.4M
in new stakes
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED4,539,007$174.0M
MORGAN STANLEYADD3,351,911$128.5M
CITADEL ADVISORS LLCDOUBLED2,779,213$106.6M
Point72 Asset Management, L.P.NEW1,852,776$71.0M
Nuveen, LLCADD1,124,633$43.1M
JANE STREET GROUP, LLCNEW752,999$28.9M
HSBC HOLDINGS PLCADD537,009$20.3M
CAISSE DE DEPOT ET PLACEMENT DU QUEBECDOUBLED445,983$17.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 48% rate it Buy or better
Strong Buy6Buy4Hold11Sell0Strong Sell0
12-month targets · 14 analysts

Price is inside the target range. Median implies +17%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Nov 9, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 6, 2026UBS
MAINTAIN
MAINTAINNeutral
Nov 6, 2026Citigroup
MAINTAIN
MAINTAINNeutral
Nov 6, 2026Stifel
MAINTAIN
MAINTAINBuy
Oct 13, 2026TD Cowen
MAINTAIN
MAINTAINHold

Insider ledger

Form 4
$0
bought · 0 insiders
$17.2M
sold · 6 insiders
DateInsiderTypeValue
Nov 10, 2026
Saxonov Serge
Chief Executive Officer
Nov 10, 2026
SELL$1.9M
Sep 22, 2026
SULIMAN SHEHNAAZ
Director
Sep 22, 2026
SELL$48.8K
Sep 22, 2026
SULIMAN SHEHNAAZ
Director
Sep 22, 2026
SELL$22.8K
Sep 22, 2026
SULIMAN SHEHNAAZ
Director
Sep 22, 2026
SELL$107.1K
Sep 22, 2026
SULIMAN SHEHNAAZ
Director
Sep 22, 2026
SELL$185.4K
Sep 22, 2026
SULIMAN SHEHNAAZ
Director
Sep 22, 2026
SELL$100.5K
Sep 22, 2026
Saxonov Serge
Chief Executive Officer
Sep 22, 2026
SELL$159.2K
Sep 22, 2026
Saxonov Serge
Chief Executive Officer
Sep 22, 2026
SELL$78.2K

Earnings setup

Estimates
−$0.04
EPS estimate, this quarter
−1101%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.04-$0.04–-$0.04-700.0%$178.6M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings
10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating…
Nov 5, 2026
Earnings result
TXG Q3 2026 Earnings: EPS $-0.15 (+43.4% vs est)
Oct 27, 2026
Press release
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating…
Sep 29, 2026
Press release
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative…
Aug 28, 2026
Press release
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026…

Short side

FINRA· Oct 30, 2026
12,473,112
shares short
-2.0%
vs prior settlement
4.1
days to cover
≈9.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 Insider
Saxonov Serge sold 31,000 shares
Chief Executive Officer @ $62.90 ($1.9M)
Nov 6, 2026 SEC
Ansuman Satpathy filed a Form 3 initial statement of beneficial ownership with the SEC, reporting no securities owned…
3 · Impact 1/10
Nov 6, 2026 SEC
Joseph E. Gilliam filed a Form 3 initial statement of beneficial ownership, reporting 31 shares of Class A Common…
3 · Impact 1/10
Nov 5, 2026 Earnings
10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science
Sep 22, 2026 Insider
SULIMAN SHEHNAAZ sold 614 shares
Director @ $79.51 ($48.8K)
Sep 22, 2026 Insider
SULIMAN SHEHNAAZ sold 292 shares
Director @ $78.20 ($22.8K)
Aug 19, 2026 Event
10x Genomics, Inc. v. Parse Biosciences, Inc.
Court ruling (ca13), Docket: 25-01618
Reddit Mentions per day, 14 days
Crowd this week 42° Neutral 0 bullish · 1 bearish
Mentions, 7 days 2 0 in posts · 2 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

28 filings · 1 bullish · 7 bearish · 3 mixed · 17 neutral
All TXG filing & press-release reports (28)